An article in BioWorld Today, Dec. 1, 1997, on IDEC Pharmaceuticals Corp. should have said the company, which received FDA approval for Rituxan (its monoclonal antibody to treat non-Hodgkin's lymphoma), also is developing a radioactive version of Rituxan for use in more advanced disease states with bulkier tumors. Phase II results for IDEC-Y2B8 — the ytrium-labeled monoclonal antibody — will be presented at the American Society of Hematology annual meeting Dec. 9.